BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $56.50 +1.07%
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $430 million versus the consensus estimate of $418.61 million.
GUIDANCE:
BioMarin Pharma sees 2020 revenue of $1.85-1.95 billion, versus the consensus of $1.9 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
- Qualcomm investor day to detail data center plans Wednesday
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
